#shingles vaccine market

[mitalipingale]

The Shingles Vaccine Market in 2023 is US$ 3.99 billion, and is expected to reach US$ 8.63 billion by 2031 at a CAGR of 10.10%.

[industryforecastnews]

Shingles Vaccine Market Size To Reach USD 11.26 Billion By 2030

Shingles Vaccine Market Growth & Trends

The global shingles vaccine market size is expected to reach USD 11.26 billion by 2030, registering a CAGR of 15.34% during the forecast period, according to a new report by Grand View Research, Inc. Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth. According to the CDC, nearly one million cases of shingles are reported each year in the United States. Furthermore, one out of three individuals in the country will develop the disease in their lifetime.

The increasing adoption of vaccines and an increase in the recommendation of vaccination by different government regulatory bodies are expected to drive the market over the forecast period. For instance, in February 2019, the U.K. Joint Committee of Vaccination and Immunization (JCVI) has recommended the use of the recombinant vaccine to prevent shingles in adults aged 60 to 70 years old.

The inclusion of shingles vaccines in national immunization programs of several countries is anticipated to propel the demand for vaccines. For instance, the shingles vaccine is a part of the national immunization program in the U.K. since 2013. The U.K. is the first country in the European region to introduce shingles vaccine in the national immunization program and it costs around USD 130 to the National Health Service (NHS) for each dose of the vaccine. Similarly, other countries such as the U.S., Italy, Australia, and some provinces of Canada and South Korea have also included the vaccine in their immunization program.

Besides, favorable initiatives undertaken by market players and regulatory bodies to increase the awareness among people who are at risk of developing the disease are expected to fuel the market growth over the coming years. For instance, GlaxoSmithKline plc. has launched a campaign to increase vaccination rates among older adults by educating people about the benefits associated with vaccination.

The high efficacy of vaccines is expected to increase the adoption over the forecast period. According to clinical trial results, Shingrix is highly efficient to prevent shingles and postherpetic neuralgia. Two doses of Shingrix are more than 90% effective to prevent the disease in adults aged 50 years and above. Protection stays above 85% for at least the first four years after getting vaccinated.

The availability of vaccines at lower prices, coupled with a high incidence of the disease and high vaccination rate in developed countries, is anticipated to fuel the market growth. The vaccination rate against shingles in the U.K., the U.S., France, Canada, Germany, and South Korea is higher compared to other countries owing to better reimbursement policies and high awareness levels regarding the disease and vaccines. For instance, the U.K. has the highest shingles vaccine uptake with more than 60% vaccination of eligible adults.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/shingles-vaccine-market-report

Shingles Vaccine Market Report Highlights

By product, Shingrix held the largest share in 2023, owing to the high efficacy of the vaccine as compared to others. Shingrix is also expected to grow at a significant CAGR over the forecast period owing to the increasing recommendations by regulatory bodies to prevent shingles

Based on vaccine type, the recombinant vaccine segment is anticipated to grow at a substantial rate over the forecast period due to the low risk associated with recombinant vaccines

Asia Pacific is projected to witness the fastest growth during the forecast period owing to the high unmet needs and the rising adoption of vaccination programs in the region

North America dominated the market in 2023, due to favorable reimbursement policies and rising initiatives to raise awareness among healthcare professionals and patients.

Shingles Vaccine Market Segmentation

Grand View Research has segmented the global shingles vaccine market based on product, type, end-use, and region:

Shingles Vaccine Product Outlook (Revenue, USD Million, 2018 - 2030)

Shingrix

Zostavax

SKYZoster

Shingles Vaccine Type Outlook (Revenue, USD Million, 2018 - 2030)

Recombinant Vaccine

Live Attenuated Vaccine

Shingles Vaccine End Use Outlook (Revenue, USD Million, 2018 - 2030)

Private Healthcare Settings

Government Healthcare Settings

Shingles Vaccine Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

Middle East and Africa (MEA)

South Africa

Saudi Arabia

Kuwait

UAE

List of Key Players of Shingles Vaccine Market

GlaxoSmithKline plc.

Merck & Co., Inc.

SK chemicals

Green Cross Corp

Geneone Life Science

Vaccitech

CanSinoBIO

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/shingles-vaccine-market-report

[bishtmeenakshi]

Vaccinating the World: Can the Market Deliver on Its Promise?

Explore the potential of the vaccine market to deliver on its promise of global immunization. Analyze trends, size, and future outlook across various vaccine segments, including pneumococcal, dengue, DNA, typhoid fever, and foot and mouth disease vaccines market.

[lazyscience]

So for my followers who come with a factory-installed uterus I know you're concerned about your health and autonomy. And you well should be

But here's something all of you should be thinking about and planning for no matter what your plumbing - if Trump goes through with putting RFK Jr. in a position of power as far as the Department of Health and Human Services, he could do a LOT of damage as far as vaccines. Vaccines are not super profitable for pharma companies, despite what cranks think; they take a LOT of development for only a few uses. Vaccines are driven by public health requirements and a lot of places would shrug and say "ok, bet" if there isn't a guaranteed market for them.

The professional medical community will still have recommendations about when and how to vaccinate, but they won't have the force of law, and insurance will probably smell blood in the water and start kicking up a fuss about covering vaccines when they're not required. So then when doctors recommend them there'll be suspicion and pushback that they're just doing it for "kickbacks" even though the only doctor who would have gotten paid for vaccine is ironically Andrew Wakefield, the lying fuckshit, because his whole "vaccines cause autism" lie was to push his OWN, SPECIAL proprietary vaccines that wouldn't cause his made-up syndrome, because NO vaccines were causing it. May he roast somewhere warm when the devil comes for him.

This will not happen immediately, but. Because there will no doubt be anticipatory compliance on the part of drug companies and healthcare systems. I HIGHLY advise you get the fuck out there and get your Tdap updated (tetanus, diptheria and pertussis). Whooping cough is out there, and it is horrible for babies. If you are eligible for shingles vaccine and haven't done it, get that. Get your COVID vax if you haven't, there might not BE another one, at least not that's available in the US.

If you have kids, especially make sure THEY'RE up to date because their classmates might very well not be mandated to get them any more - state regulations will undoubtedly vary, but with the current composition of the Court, it will rule in favor of every possible exemption for antivaxxers as possible because the conservatives are all "fuck the weakest of us, I got mine fuck you." And expect idiocy like "pox parties" to spread (not like the average suburban parent can tell measles from rubella from chicken pox from hand foot and mouth by fuckin' looking at it, who knows what the christ they're going to be passing around). Measles is NOT just a "bit of a rash." Rubella is the world's leading preventable cause of birth defects. Chickenpox can result in scarring, encephalitis causing blindness or even death, and the risk of shingles later in life. I have a cousin who would be 57 this year who died as a toddler from hemophilus influenzae strain B meningitis, one of those "too many" childhood vaccines that were invented in the 1990s. Tell my aunt that's too many vaccines -oh, wait, you can't, she fucking killed herself out of grief her baby died.

tweens? get them the HPV vaccine if they haven't gotten it (given its associations with sex it'll probably be one of the first to go, but it prevents CANCER. who wants their child to get cervical cancer, or penile cancer, or throat cancer, or rectal cancer? IT PREVENTS CANCER. JUST DO IT.)

Similarly, if you have a child with any kind of immune issue that precludes vaccination, I would very much look into homeschooling, because bye-bye herd immunity.

If you have teenage kids, encourage them to update their Tdap and get the meningiococcal meningitis vaccine if they haven't been mandated to already by campus policy. Tetanus and meningitis aren't common, but they are frequently permanently life-altering when they're not fatal. We're talking months in the hospital. I'm old enough that I remember people fucking dying in college, and the panic that went around campus every time one of those breakouts happened in the state wondering if it would make its way to our campus.

Stay safe out there. I have no idea what this will do to our already teetering healthcare system but I don't think it'll be pretty. Everybody pray Trump pulls his usual scam and hangs RFK Jr. out to dry, because while the plutocrats consider regulations an unnecessary burden, they don't have a stake in creating a public health state of emergency when we already have a workforce not keeping up with demand, unlike Captain Convenient Brain Worm.

[thoughtportal]

Oprah went on the air nationally in the 1980s, just as non-Christian faith healing and channeling the spirits of the dead and “harmonic convergence” and alternative medicine and all the rest of the New Age movement had scaled up. By the 1990s, there was a big, respectable, glamorous New Age counterestablishment. Marianne Williamson, one of the new superstar New Age preachers, popularized a “channeled” book of spiritual revelation, A Course in Miracles: The author, a Columbia University psychology professor who was anonymous until after her death in the 1980s, had claimed that its 1,333 pages were dictated to her by Jesus. Her basic idea was that physical existence is a collective illusion—”the dream.” Endorsed by Williamson, the book became a gigantic best-seller. Deepak Chopra had been a distinguished endocrinologist before he quit regular medicine in his 30s to become the “physician to the gods” in the Transcendental Meditation organization and in 1989 hung out his own shingle as wise man, author, lecturer, and marketer of dietary supplements.

Remember the satanic panic, the mass hysteria during the 1980s and early ’90s about satanists abusing and murdering children that resulted in the wrongful convictions of dozens of people who collectively spent hundreds of years incarcerated? Multiple Oprah episodes featured the celebrity “victims” who got that fantasy going.

Most of the best-known prophets and denominational leaders in the New Age realm owe their careers to Winfrey. Her man Eckhart Tolle, for instance, whose books The Power of Now and A New Earth sold millions of copies apiece, is a successful crusader against reason itself. “Thinking has become a disease,” he writes, to be supplanted by feeling “the inner energy field of your body.”

Oz has encouraged viewers to believe that vaccines cause autism and other illnesses—as did Winfrey on her show before him. In 2007, long after the fraudulent 1998 paper that launched the anti-vaccine movement had been discredited, she gave an Oprah episode over to the actress Jenny McCarthy, a public face of the movement.

[jo1027]

German Doctor Exposes Monkey Pox Scam: Says It's a COVID-19 Vaccine Side Effect.

From the German article titled: Doctor: Monkeypox is actually shingles, a side effect of the COVID vaccines

The main symptom of monkeypox is the rash that can look like blisters and is accompanied by severe pain. This is also typical for herpes zoster, or shingles, noted doctor Wolfgang Wodarg earlier in an interview with Austrian broadcaster AUF1.

Shingles is a skin disease in which the affected person develops blisters on the skin that resemble chickenpox.

Shingles is also a known side effect of the corona vaccine. Attorney Aaron Siri made sure that 390,000 reports from the monitoring system V-safe of the American health service CDC were made public. It shows that 1 in 450 people reported shingles after vaccination.

According to Wodarg, the expensive PCR tests that pharmaceutical giant Roche has launched on the market to detect the monkeypox virus are not reliable. He argues that they are now making people afraid of diseases that are actually side effects of the corona vaccinations.

The side effects of the Covid vaccines are being used to scare us about other conditions, the doctor stresses, who speaks of a 'perverse industry'.

JOIN: Barbara O’Neill (https://t.me/+Y2RqGNhLHKU4OTc5) ✅️

[heathcareforallworld]

Growth in the Shingles Treatments Market

The shingles treatments market is a critical component of the global healthcare landscape, driven by the increasing prevalence of shingles, also known as herpes zoster, and the growing awareness of its complications. Shingles is a viral infection caused by the varicella-zoster virus, the same virus responsible for chickenpox. After a person recovers from chickenpox, the virus can remain dormant in nerve tissues and reactivate later in life, leading to shingles. This painful condition primarily affects older adults and individuals with weakened immune systems, making it a significant public health concern. This article delves into the current market size and share of shingles treatments, explores key industry trends, and provides insights into the factors shaping the market.

Market Size and Share

Shingles treatments Market Size was estimated at 3.01 (USD Billion) in 2023. The Shingles Treatments Market Industry is expected to grow from 3.13(USD Billion) in 2024 to 4.2 (USD Billion) by 2032. The shingles treatments Market CAGR (growth rate) is expected to be around 3.76% during the forecast period (2024 - 2032).This growth is primarily driven by the increasing incidence of shingles, an aging global population, and the rising awareness of the importance of early treatment and vaccination.

North America currently dominates the shingles treatments market, accounting for nearly 45% of the global market share. The high prevalence of shingles in the region, coupled with the availability of advanced healthcare facilities and widespread awareness, has contributed to this dominance. Europe follows closely, with a significant market share driven by similar factors. The Asia-Pacific region is anticipated to experience the fastest growth, attributed to increasing healthcare expenditure, rising awareness, and a growing aging population.

Industry Trends

Rising Prevalence of Shingles: The increasing incidence of shingles is one of the primary drivers of the market. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 3 people in the United States will develop shingles in their lifetime, with around 1 million cases diagnosed each year. The risk of developing shingles increases with age, particularly in individuals over 50. This growing prevalence underscores the need for effective treatment options, driving the demand for antiviral medications, pain management therapies, and vaccines.

Advancements in Antiviral Therapies: Antiviral medications are the cornerstone of shingles treatment, helping to reduce the severity and duration of the illness. The market has seen significant advancements in antiviral therapies, with newer drugs offering improved efficacy and fewer side effects. Commonly used antiviral drugs include acyclovir, valacyclovir, and famciclovir, which are effective in reducing the replication of the varicella-zoster virus. Ongoing research and development in this area are expected to lead to the introduction of more potent and convenient antiviral options.

Increased Focus on Vaccination: Vaccination is a crucial preventive measure against shingles, particularly for older adults. The introduction of vaccines such as Zostavax and Shingrix has significantly impacted the shingles treatment market. Shingrix, in particular, has gained widespread acceptance due to its high efficacy rate of over 90% in preventing shingles and its complications, including postherpetic neuralgia (PHN). The growing emphasis on vaccination, driven by public health campaigns and recommendations from healthcare authorities, is expected to boost the market for shingles vaccines.

Growing Awareness of Complications: Shingles can lead to serious complications, the most common of which is postherpetic neuralgia (PHN), a condition characterized by persistent nerve pain that can last for months or even years after the rash has healed. The increasing awareness of these complications is driving the demand for comprehensive treatment options that address both the acute phase of the illness and its long-term effects. This includes the use of pain management therapies, such as analgesics, corticosteroids, and nerve blocks, in addition to antiviral medications.

Development of Combination Therapies: The market is witnessing a growing interest in combination therapies that target multiple aspects of shingles treatment. For example, combining antiviral medications with pain management therapies or corticosteroids can help improve patient outcomes by addressing both the viral infection and the associated pain and inflammation. This trend towards combination therapies is expected to drive innovation and expand the range of treatment options available to patients.

Telemedicine and Remote Care: The COVID-19 pandemic has accelerated the adoption of telemedicine and remote healthcare services, a trend that is also impacting the shingles treatments market. Telemedicine allows healthcare providers to diagnose and manage shingles remotely, ensuring that patients receive timely treatment without the need for in-person visits. This approach is particularly beneficial for older adults and individuals with mobility issues, who may find it challenging to access traditional healthcare facilities.

Increasing R&D Investments: The shingles treatments market is witnessing increased investments in research and development, with pharmaceutical companies focusing on developing new and improved therapies. This includes the exploration of novel antiviral agents, vaccines, and pain management solutions. The growing pipeline of potential treatments, coupled with ongoing clinical trials, is expected to contribute to the market's expansion in the coming years.

Focus on Pain Management: Managing the pain associated with shingles, particularly PHN, is a critical aspect of treatment. The market is seeing a growing emphasis on developing effective pain management therapies, including topical analgesics, anticonvulsants, antidepressants, and nerve blocks. These treatments aim to alleviate the severe and often debilitating pain that can accompany shingles, improving the quality of life for affected individuals.

Awareness and Education Campaigns: Public health organizations and healthcare providers are increasingly focusing on awareness and education campaigns to inform the public about shingles, its risks, and the importance of early treatment and vaccination. These campaigns are crucial in encouraging older adults to seek preventive care and timely treatment, thereby driving the demand for shingles-related healthcare services.

Regional Disparities in Access to Treatment: While the market is growing globally, there are significant regional disparities in access to shingles treatment and vaccination. In high-income countries, access to antiviral medications and vaccines is widespread, while in low- and middle-income countries, access may be limited due to cost and availability. Addressing these disparities is essential for ensuring equitable access to shingles treatments worldwide.

Aging Population and Healthcare Needs: The global population is aging, with the number of people aged 60 and over expected to reach 2.1 billion by 2050. This demographic shift is driving the demand for healthcare services, including shingles treatments, as older adults are more susceptible to the virus. The increasing healthcare needs of this population are expected to be a significant driver of market growth over the next decade.

Conclusion

The shingles treatments market is poised for substantial growth over the next decade, driven by the rising prevalence of shingles, advancements in antiviral therapies, and the increasing focus on vaccination and pain management. As the global population ages and awareness of the complications associated with shingles grows, the demand for effective treatment options is expected to increase. With ongoing research and development, the market is likely to see the introduction of new and improved therapies, further expanding the range of options available to patients.

[thegadlingguides]

The Quality of Things

I have already mentioned that I like some of the inventions/products of the past century or so, and I dislike others.

Part of that is remembering what those new products/innovations replaced, and whether the product launch succeeded because they actually worked better, because they had a lower upfront cost, or just because they were marketed better, like tar-paper roofing. I mean seriously, that used to be a sign of poverty, but there are now mega rich people who happily buy tar-paper shingle roofs (with a little artful crushed gravel stuck on for color).

My top four favorite things popularized in the past century or two are: Washers (for laundry) Vaccines Hot Showers Dishwashers Honorable mention: Trains

My least favorite innovations/products are: Fossil fuels Polyester used for clothing Hydrogenated oils in food High fructose corn syrup Particle board (Things like DDT, Roundup, and Forever Chemicals in nonstick cookware have already been publicly debunked as harmful, so I won't be giving a full list of those)

Some things have their place in the global market, but are lower quality than the product they replaced, or got over-used in a problematic way: Cotton (water intensive to grow, inferior structural properties to linen) Rayon (highly flammable, but very recyclable) Concrete (CO2 intensive, prone to cracking rather then settling/re-sealing over time) Chemical fertilizers (disastrously over-used, replaced traditional farming methods in conjunction with colonial practices) Antibiotics (Amazing, but also disastrously over-used)

-

This list evolves over time. At one point, I'm pretty sure 'sugar of lead' was on it. The point is to keep a sort of backup disc to counteract the loss of materiel knowledge when a well-marketed but inferior or dangerous product takes over for a generation of two. -You think 'moisture wicking technology' is reserved for synthetic fabrics, try Linen.

[mitalipingale]

https://www.pittsburghtribune.org/read-blog/116310_shingles-vaccine-market-share-overview-competitive-analysis-and-forecast-2031.html

The Shingles Vaccine Market in 2023 is US$ 3.99 billion, and is expected to reach US$ 8.63 billion by 2031 at a CAGR of 10.10%.

[decentralvaccine]

Shingles Vaccine May Protect Against Dementia

Wendy Williams has it. Bruce Willis has it. Tony Bennett had it. So did Gene Wilder. Dementia is currently killing around seven million Americans, in one of the cruelest ways imaginable, and a staggering 55 million around the world. And still nobody knows what causes it.

But scientists at drugs giant GSK think they may have a drug that helps protect against it—and it’s already on the market.

Company chief commercial officer Luke Miels says GSK internal data is showing “a correlation” between those who had taken the company’s shingles vaccine, Shingrix, and a lower risk of getting dementia.

https://www.marketwatch.com/amp/story/our-shingles-vaccine-may-help-protect-against-dementia-says-big-pharma-exec-46e4bf8c

[omkarpatel]

Adult Vaccines Market is Estimated to Witness High Growth Owing to Opportunity of Reduction in Disease Burden

Adult vaccines are primarily used in immunizing adults against diseases such as hepatitis, influenza, pneumonia and herpes zoster. These vaccines help protect individuals against severe illnesses and reduce the disease burden. Adult vaccines are usually prescribed for individuals above 18 years of age or for those entering adulthood. They are important in reducing risks of vaccine preventable diseases and controlling epidemic outbreaks. The global Adult Vaccines Market is estimated to be valued at US$ 16,790.11 Mn in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The opportunity for reduction in disease burden is expected to drive significant growth of the adult vaccines market. Preventing diseases through vaccination can significantly reduce illness, disability and mortality among adults. Widespread adult vaccination programs can substantially lower the burden of many vaccine-preventable diseases globally. For instance, vaccination against influenza and pneumonia is crucial to protect adults from severe complications arising from these conditions. These vaccines can prove beneficial in reducing hospitalization, medical costs and loss of productivity associated with such diseases. Similarly, vaccination of adults against hepatitis B and herpes zoster significantly cuts down the risk of chronic liver disease and painful complications of shingles later in life. Effective vaccination coverage in older adults thus presents a major market opportunity to lower disease prevalence rates. This in turn is projected to augment demand for adult vaccines over the forecast period. Porter's Analysis Threat of new entrants: Low- Medium. Significant capital is required to conduct R&D and bring new vaccines to market. Regulatory barriers also exist. Bargaining power of buyers: Medium. A large customer base of healthcare providers and govts who purchase vaccines. Market consolidated with few major players. Bargaining power of suppliers: Low. Major pharma companies control intellectual property and production. Suppliers have less influence on prices. Threat of new substitutes: Low. Limited substitute prevention measures compared to effectiveness of vaccines. Competitive rivalry: High. Major players compete on innovation, pricing and market share. SWOT Analysis Strengths: Growing aging population worldwide increases market. Vaccines save on long term healthcare costs. Weaknesses: Low awareness in developing nations. Vaccine hesitancy and refusals impact uptake rates. Opportunities: Development of immunotherapies and combo vaccines presents scope. Untapped potential in certain countries. Threats: Stringent regulations delay products. Outbreaks can impact demand prognosis. Vaccine price control policies hurt revenue. Key Takeaways The global Adult Vaccines market is expected to witness high growth over the forecast period of 2023 to 2030. The market size is projected to grow from US$ 16,790.11 Mn in 2023 to US$ 33,678.42 Mn by 2030 at a CAGR of 7.1%. Key players operating in the adult vaccines market are GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc. Major players are focused on expanding their portfolio through acquisitions and new product launches.

[fostertheory]

Elder Millennials and older, people who survived chicken pox, are now at risk of developing shingles because the varicella virus lives on in your nervous system and re-emerges later in life. It was most recently in the news because Dianne Feinstein was hospitalized for a couple of months because of it.

There is a two-dose vaccine on the market that is highly effective at preventing shingles. Go get ‘em!

[1-2-3-4-4498-0]

Solar Energy and Health: The Vaccine Refrigeration Revolution

Solar-powered vaccine refrigerator Market are designed to store vaccines and other medical products at a stable temperature to ensure they do not degrade. In developing countries with a sunny climate, solar-powered vaccine refrigerators are common. Many vaccines must be stored at low temperatures, some below -15 °C, and others between 2 and 8 °C. If vaccines are not stored correctly, they can lose their effectiveness.

The ideal temperature for storing vaccines in the ILR is +2 degrees to + 8 degrees According to the Centre for Disease Control, failure to adhere to recommended specifications for storage and handling of immunobiology’s can reduce or destroy their potency, resulting in inadequate or no immune response in the recipient. Maintenance of vaccine quality is the shared responsibility of all handlers of vaccines from the time a vaccine is manufactured until administration. According to the Immunization Action Coalition, all vaccines should be stored in a refrigerator or freezer that is designed specifically for the storage of biologics or, alternatively, in a separate dedicated unit. 

A dorm-style combination refrigerator-freezer unit with just one exterior door has been shown to be unacceptable no matter where the vaccine was placed inside the unit. Stand-alone refrigerator or freezer units are best for storage needs. With retail pharmacies now playing a major role in pneumonia, influenza and shingles immunization programs, the value of critical vaccines being stored in pharmacy refrigerators has reached a new high. In fact, it is not uncommon for many pharmacies to now have over $100,000 of product in a single refrigerator during peak seasons.

COVID-19 Impact analysis

The COVID pandemic, and now finally, the vaccination push across the world against the disease has put the spotlight firmly on the role distributed solar products, particularly Solar refrigeration could play

Rockwell Industries Ltd, a commercial cold chain appliances manufacture, Thursday launched its new product called ‘Chillermill’ here. The product is both a freezer and chiller useful to store COVID-19 vaccine at the required temperatures.

The Vaccine Alliance — began buying and installing solar-powered fridges to store vaccines throughout the region. The idea would be a gamechanger for regional and district health workers who often struggle to carry out routine immunizations for children in places with unreliable electricity and cold storage facilities.

Top Impacting Factors

Solar refrigeration was an encouraging development in the early 1980s, providing a substitute for the absorption technology to meet cold chain requirements in remote areas with finite or no electric power. At present, various solar refrigeration models prequalified by the World Health Organization (WHO) are in use. A fresh approach in solar-based refrigeration has emerged, wherein the newly designed solar refrigerator has gotten rid of the need for high priced energy storage batteries employed to power solar refrigerators. This technology called solar direct drive technology uses solar energy to directly freeze water or other cold storage material (for instance, refrigerant) and then, uses the energy stored in the frozen bank to keep the refrigerator cold during nights and rainy days when the upcoming solar energy is not within easy reach.

Market Trends

Solar-powered vaccine refrigerators, also called off-grid photovoltaic (PV) systems, are put to use to maintain a continues temperature suitable for storing vaccines in clinics

In solar-powered vaccine refrigerators, photovoltaic modules transmute the solar energy directly into electricity, which is further employed to power the compressor of the vaccine refrigerator. On the other hand, rechargeable batteries are also used to store electric energy. The charge controller regulates the flow of electricity to protect batteries from over-discharging and overcharging.

Use of solar-based refrigeration for vaccine storage is a major development in the global health care industry. It is useful for remote areas, where electricity is not available in sufficient amounts. The global health care industry has witnessed rapid growth in the recent years. Growing elderly population worldwide, high prevalence of chronic diseases, and advancements in innovative digital technologies are some of the major factors driving the global health care industry.

Electricity rates are inherently turbulent. They fluctuate seasonally, monthly, and annually. Over the last decade, electricity prices had increased enormously and they are poised to increase even more during the forecast period. This, in turn, is projected to rise the demand for use of the solar technology for storage of vaccines in the near future.

There exists high demand for exploration of sustainable and clean sources for energy, as the world tries to limit emissions and targets to reach net zero carbon emissions

Government support in the form of favorable initiatives has driven usage of the solar technology over the last few years. This is estimated to be a major factor driving the global solar-powered vaccine refrigerator market during the forecast period. For instance, the Solar Energy Corporation of India (SECI) has passed a tender, wherein the government would be offering 30% subsidy to the social sector, the residential sector, private and not-for-profit organizations in the field of education, and health care institutions.

Key Benefits of the Report

This study presents the analytical depiction of the Solar-powered vaccine refrigerator industry along with the current trends and future estimations to determine the imminent investment pockets.

The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Solar-powered vaccine refrigerator market share.

The current market is quantitatively analyzed from 2020 to 2030 to highlight the Solar-powered vaccine refrigerator market growth scenario.

Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.

The report provides a detailed Solar-powered vaccine refrigerator market analysis based on competitive intensity and how the competition will take shape in coming years.

Key Market Players : ACMAS Technologies (P) Ltd KYOCERA Corporation, QINGDAO HERALD CRYOGENIC TECHNOLOGY CO., LTD, Godrej Appliances,, Qingdao Amed Commercial Refrigeration Equipment Co., Ltd, RuthurEnergy Limited, Meditech Technologies India Private Limited, Sure Chill, Haier, Vestfrost Solutions,, Neumann & Miller, Dulas Ltd., Renaissance Energy Systems, Sundanzer

[newscoffe]

GSK signs shingles vaccine deal with China's Zhifei for around $3 bln

LONDON/SHANGHAI Oct 9 (Reuters) - China's largest vaccines company Zhifei (300122.SZ) will pay British drugmaker GSK (GSK.L) 2.5 billion pounds ($3.05 billion) for the exclusive rights to distribute GSK's shingles vaccine in the world's No.2 pharmaceuticals market.

[sonicnews100]

GSK signs shingles vaccine deal with China's Zhifei for around $3 bln

LONDON/SHANGHAI Oct 9 (Reuters) - China's largest vaccines company Zhifei (300122.SZ) will pay British drugmaker GSK (GSK.L) 2.5 billion pounds ($3.05 billion) for the exclusive rights to distribute GSK's shingles vaccine in the world's No.2 pharmaceuticals market.

[blogynews]

"Game-Changing Partnership: GSK and Zhifei Unleash Groundbreaking Vaccines in China"

Global pharmaceutical company GlaxoSmithKline (GSK) announced today that it has entered into a definitive and exclusive agreement with Zhifei Biological Products Co., Ltd. (Zhifei) to collaboratively promote their highly effective shingles vaccine, Shingrix, in the vast Chinese market. This groundbreaking partnership aims to address the significant unmet medical need for preventing shingles…